200 related articles for article (PubMed ID: 36401094)
1. Castration-resistant prostate cancer cells are dependent on the high activity of CDK7.
Pallasaho S; Gondane A; Kuivalainen A; Girmay S; Moestue S; Loda M; Itkonen HM
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5255-5263. PubMed ID: 36401094
[TBL] [Abstract][Full Text] [Related]
2. O-GlcNAc transferase couples MRE11 to transcriptionally active chromatin to suppress DNA damage.
Gondane A; Girmay S; Helevä A; Pallasaho S; Loda M; Itkonen HM
J Biomed Sci; 2022 Feb; 29(1):13. PubMed ID: 35164752
[TBL] [Abstract][Full Text] [Related]
3. CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation.
Rasool RU; Natesan R; Deng Q; Aras S; Lal P; Sander Effron S; Mitchell-Velasquez E; Posimo JM; Carskadon S; Baca SC; Pomerantz MM; Siddiqui J; Schwartz LE; Lee DJ; Palanisamy N; Narla G; Den RB; Freedman ML; Brady DC; Asangani IA
Cancer Discov; 2019 Nov; 9(11):1538-1555. PubMed ID: 31466944
[TBL] [Abstract][Full Text] [Related]
4. The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer.
Constantin TA; Varela-Carver A; Greenland KK; de Almeida GS; Olden E; Penfold L; Ang S; Ormrod A; Leach DA; Lai CF; Ainscow EK; Bahl AK; Carling D; Fuchter MJ; Ali S; Bevan CL
Br J Cancer; 2023 Jun; 128(12):2326-2337. PubMed ID: 37076563
[TBL] [Abstract][Full Text] [Related]
5. Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer.
Zhao N; Peacock SO; Lo CH; Heidman LM; Rice MA; Fahrenholtz CD; Greene AM; Magani F; Copello VA; Martinez MJ; Zhang Y; Daaka Y; Lynch CC; Burnstein KL
Sci Transl Med; 2019 Jun; 11(498):. PubMed ID: 31243151
[TBL] [Abstract][Full Text] [Related]
6. Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures.
Chattopadhyay I; Wang J; Qin M; Gao L; Holtz R; Vessella RL; Leach RW; Gelman IH
Oncotarget; 2017 Feb; 8(6):10324-10347. PubMed ID: 28055971
[TBL] [Abstract][Full Text] [Related]
7. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
8. Androgen-repressed lncRNA LINC01126 drives castration-resistant prostate cancer by regulating the switch between O-GlcNAcylation and phosphorylation of androgen receptor.
Cai Y; Chen M; Gong Y; Tang G; Shu Z; Chen J; Zhou H; He Y; Long Z; Gan Y
Clin Transl Med; 2024 Jan; 14(1):e1531. PubMed ID: 38214432
[TBL] [Abstract][Full Text] [Related]
9. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
[TBL] [Abstract][Full Text] [Related]
10. Androgen suppresses the proliferation of androgen receptor-positive castration-resistant prostate cancer cells via inhibition of Cdk2, CyclinA, and Skp2.
Kokontis JM; Lin HP; Jiang SS; Lin CY; Fukuchi J; Hiipakka RA; Chung CJ; Chan TM; Liao S; Chang CH; Chuu CP
PLoS One; 2014; 9(10):e109170. PubMed ID: 25271736
[TBL] [Abstract][Full Text] [Related]
11. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
Patki M; Huang Y; Ratnam M
Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of hedgehog and androgen receptor signaling pathways produced synergistic suppression of castration-resistant prostate cancer progression.
Gowda PS; Deng JD; Mishra S; Bandyopadhyay A; Liang S; Lin S; Mahalingam D; Sun LZ
Mol Cancer Res; 2013 Nov; 11(11):1448-61. PubMed ID: 23989930
[TBL] [Abstract][Full Text] [Related]
13. Antiandrogenic Effects of a Polyphenol in
Kudo Y; Endo S; Tanio M; Saka T; Himura R; Abe N; Takeda M; Yamaguchi E; Yoshino Y; Arai Y; Kashiwagi H; Oyama M; Itoh A; Shiota M; Fujimoto N; Ikari A
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430833
[TBL] [Abstract][Full Text] [Related]
14. Mediator kinase inhibition reverses castration resistance of advanced prostate cancer.
Li J; Hilimire TA; Liu Y; Wang L; Liang J; Gyorffy B; Sikirzhytski V; Ji H; Zhang L; Cheng C; Ding X; Kerr KR; Dowling CE; Chumanevich AA; Mack ZT; Schools GP; Lim CU; Ellis L; Zi X; Porter DC; Broude EV; McInnes C; Wilding G; Lilly MB; Roninson IB; Chen M
J Clin Invest; 2024 Mar; 134(10):. PubMed ID: 38546787
[TBL] [Abstract][Full Text] [Related]
15. Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription.
Jia L; Wu D; Wang Y; You W; Wang Z; Xiao L; Cai G; Xu Z; Zou C; Wang F; Teoh JY; Ng CF; Yu S; Chan FL
Oncogene; 2018 Jun; 37(25):3340-3355. PubMed ID: 29555975
[TBL] [Abstract][Full Text] [Related]
16. The kinesin KIF20A promotes progression to castration-resistant prostate cancer through autocrine activation of the androgen receptor.
Copello VA; Burnstein KL
Oncogene; 2022 May; 41(20):2824-2832. PubMed ID: 35418689
[TBL] [Abstract][Full Text] [Related]
17. Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer.
Zheng D; Gui B; Gray KP; Tinay I; Rafiei S; Huang Q; Sweeney CJ; Kibel AS; Jia L
Oncogene; 2016 Sep; 35(36):4807-15. PubMed ID: 26876202
[TBL] [Abstract][Full Text] [Related]
18. MED15, encoding a subunit of the mediator complex, is overexpressed at high frequency in castration-resistant prostate cancer.
Adler D; Menon R; Braun M; Offermann A; Queisser A; Boehm D; Vogel W; Rüenauver K; Ruiz C; Zellweger T; Svensson M; Andren O; Kristiansen G; Wernert N; Bubendorf L; Kirfel J; Biskup S; Perner S
Int J Cancer; 2014 Jul; 135(1):19-26. PubMed ID: 24374838
[TBL] [Abstract][Full Text] [Related]
19. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
Moll JM; Hofland J; Teubel WJ; de Ridder CMA; Taylor AE; Graeser R; Arlt W; Jenster GW; van Weerden WM
Prostate; 2022 Apr; 82(5):505-516. PubMed ID: 35037287
[TBL] [Abstract][Full Text] [Related]
20. Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer.
Denmeade SR; Sena LA; Wang H; Antonarakis ES; Markowski MC
Oncologist; 2023 Jun; 28(6):465-473. PubMed ID: 37027449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]